Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Health systems and care delivery

Topic: Risk, prevention and care in population studies

Plain-language summary

To estimate the risk of ischaemic stroke associated with antidopaminergic antiemetic (ADA) use. Case-time-control study. Data from the nationwide French reimbursement healthcare system database Système National des Données de Santé (SNDS). Eligible participants were ≥18 years with a first ischaemic stroke between 2012 and 2016 and at least one reimbursement for any ADA in the 70 days before stroke. Frequencies of ADA reimbursements were compared for a risk period (days -14 to -1 before stroke) and three matched reference periods (days -70 to -57, -56 to -43, and -42 to -29) for each patient. Time trend of ADA use was controlled by using a control group of 21 859 randomly selected people free of the event who were individually matched to patients with stroke according to age, sex, and risk factors of ischaemic stroke. Association between ADA use and risk of ischaemic stroke was assessed by estimating the ratio of the odds ratios of exposure evaluated in patients with stroke and in controls. Analyses were adjusted for time varying confounders (anticoagulants, antiplatelets, and prothrombotic or vasoconstrictive drugs). Among the 2612 patients identified with incident stroke, 1250 received an ADA in the risk period and 1060 in the reference periods. The comparison with the 5128 and 13 165 controls who received an ADA in the same periods yielded a ratio of adjusted odds ratios of 3.12 (95% confidence interval 2.85 to 3.42). Analyses stratified by age, sex, and history of dementia showed similar results. Ratio of adjusted odds ratios for analyses stratified by ADA was 2.51 (2.18 to 2.88) for domperidone, 3.62 (3.11 to 4.23) for metopimazine, and 3.53 (2.62 to 4.76) for metoclopramide. Sensitivity analyses suggested the risk would be higher in the first days of use. Using French nationwide exhaustive reimbursement data, this self-controlled study reported an increased risk of ischaemic stroke with recent ADA use. The highest increase was found for metopimazine and metoclopramide.

What this study adds

Evidence grade: Low

The record lists 2,612 participants. This study found an increased risk of ischaemic stroke with recent use of antidopaminergic antiemetic medicines, and results were similar in people with a history of dementia. It is about stroke risk from these medicines, not about treating, curing, or preventing Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Anne, B.-L., Emilie, H., Stéphanie, D., Julien, K., Julien, B., & Antoine, P. (2022). Risk of first ischaemic stroke and use of antidopaminergic antiemetics: nationwide case-time-control study. BMJ (Clinical research ed.). https://doi.org/10.1136/bmj-2021-066192

Vancouver

Anne B.-L, Emilie H, Stéphanie D, Julien K, Julien B, Antoine P. Risk of first ischaemic stroke and use of antidopaminergic antiemetics: nationwide case-time-control study. BMJ (Clinical research ed.). 2022. doi:10.1136/bmj-2021-066192. PMID: 35321876.

BibTeX

@article{anne2022-35321876,
  author  = {Anne, Bénard-Laribière and Emilie, Hucteau and Stéphanie, Debette and Julien, Kirchgesner and Julien, Bezin and Antoine, Pariente},
  title   = {{Risk of first ischaemic stroke and use of antidopaminergic antiemetics: nationwide case-time-control study}},
  journal = {BMJ (Clinical research ed.)},
  year    = {2022},
  doi     = {10.1136/bmj-2021-066192},
  pmid    = {35321876},
  url     = {https://doi.org/10.1136/bmj-2021-066192}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This study found an increased risk of ischaemic stroke with recent use of antidopaminergic antiemetic medicines, and results were similar in people with a history of dementia. It is about stroke risk from these medicines, not about treating, curing, or preventing Alzheimer's disease.

Study details

How this study scored 45/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 3 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 43 of the 96 points it could be judged on, which is 45 of 100. Total 45 of 100.43 of the 96 points we could judge = 45 of 100

Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 43 of the 96 points we could judge it on, which is 45 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (BMJ (Clinical research ed.))
Journal's citation record 3 / 4 BMJ: journal h-index 413 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2022 — within 6 year(s) of the newest study here
Sample size 3 / 4 2,612 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 10 times (OpenAlex, 2026-10-17)
Citations per year 1 / 5 1.7 citations a year over 6 year(s) since 2022
Impact for its field and year 2 / 6 Cited 1.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record 2 / 3 Inserm: institution h-index 1,988 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 7 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 35321876)
Free to read 0 / 2 Behind a paywall — scores zero
Points 43 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 43 of the 96 points we could judge it on is 45 out of 100.
Total 45 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Health systems and care delivery from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Health systems and care delivery

See all studies in Health systems and care delivery →